

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 March 2022 (17.03.2022)



(10) International Publication Number
WO 2022/056448 A1

(51) International Patent Classification:

C07D 471/18 (2006.01) A61P 7/06 (2006.01)
C07D 471/22 (2006.01) A61P 37/00 (2006.01)
C07D 471/08 (2006.01) A61K 31/439 (2006.01)
A61P 3/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2021/050212

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(22) International Filing Date:

14 September 2021 (14.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/078,118 14 September 2020 (14.09.2020) US
63/229,338 04 August 2021 (04.08.2021) US

(71) Applicant: **SANOFI** [FR/FR]; 54 rue La Boétie, 75008
Paris (FR).

(72) Inventors: **BARBERIS, Claude**; c/o Sanofi U.S., 55 Cor-
porate Drive, Mail Code: 55A-525, Bridgewater, New Jer-
sey 08807 (US). **KARAGEORGE, George**; c/o Sanofi
U.S., 55 Corporate Drive, Mail Code: 55A-525, Bridgewa-
ter, New Jersey 08807 (US). **JURCAK, John**; c/o Sanofi
U.S., 55 Corporate Drive, Mail Code: 55A-525, Bridgewa-
ter, New Jersey 08807 (US). **TERRANOVA, Kristen**; c/
o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-525,
Bridgewater, New Jersey 08807 (US).

(74) Agent: **TANNER, Lorna L.** et al.; SHEPPARD MULLIN
RICHTER & HAMPTON LLP, 650 Town Center Drive,
10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF RED BLOOD DISORDERS AND IN-
FLAMMATORY DISEASES

(57) Abstract: Provided herein are compounds and compositions thereof for activating nuclear factor erythroid 2-related factor 2 (Nrf2)
for treating red blood cell diseases and inflammatory diseases.

WO 2022/056448 A1